Literature DB >> 2036217

Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors.

H Nielsen1, H J Nielsen, N Tvede, K Klarlund, B Mansa, F Moesgaard, A Drivsholm.   

Abstract

Multiple myeloma (MM) is characterized by an increased susceptibility to infections and to other malignancies. Selected related immune functions were studied. Spontaneous and interleukin-2-stimulated natural killer (NK) cell activities were normal in 19 patients with MM compared with 62 controls. In contrast, interferon-stimulated NK cells had a significantly lower increase in activity in MM than in controls. The normal improvement in lytic NK cell activity after addition of indomethacin to the mononuclear cell cultures (to inhibit prostaglandin-mediated suppression) was not observed in cultures from MM patients. As reported for other lymphoproliferative disorders, the levels of soluble interleukin-2 receptors in serum were significantly higher in MM (600 U/ml median value) compared with controls (317 U/ml median value), P less than 0.0001, and the concentration of interleukin-2 receptors was significantly correlated with the concentration of monoclonal immunoglobulin in serum. Blood monocyte chemotactic responsiveness was significantly lower in MM patients with both zymosan-activated serum and f-Met-Leu-Phe as cytotaxins, suggesting reduced ability to accumulate at inflammatory foci. In contrast, release of reactive oxygen radicals, believed to be associated with the killing ability of monocytes, was normal after in vitro stimulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2036217     DOI: 10.1111/j.1699-0463.1991.tb05159.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  10 in total

1.  A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Authors:  Don M Benson; Adam D Cohen; Sundar Jagannath; Nikhil C Munshi; Gary Spitzer; Craig C Hofmeister; Yvonne A Efebera; Pascale Andre; Robert Zerbib; Michael A Caligiuri
Journal:  Clin Cancer Res       Date:  2015-05-21       Impact factor: 12.531

2.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

Authors:  Don M Benson; Courtney E Bakan; Anjali Mishra; Craig C Hofmeister; Yvonne Efebera; Brian Becknell; Robert A Baiocchi; Jianying Zhang; Jianhua Yu; Megan K Smith; Carli N Greenfield; Pierluigi Porcu; Steven M Devine; Rinat Rotem-Yehudar; Gerard Lozanski; John C Byrd; Michael A Caligiuri
Journal:  Blood       Date:  2010-05-11       Impact factor: 22.113

Review 3.  Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.

Authors:  Alessandro Allegra; Marco Casciaro; Elena Lo Presti; Caterina Musolino; Sebastiano Gangemi
Journal:  Biomolecules       Date:  2022-05-27

4.  A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.

Authors:  Don M Benson; Craig C Hofmeister; Swaminathan Padmanabhan; Attaya Suvannasankha; Sundar Jagannath; Rafat Abonour; Courtney Bakan; Pascale Andre; Yvonne Efebera; Jérôme Tiollier; Michael A Caligiuri; Sherif S Farag
Journal:  Blood       Date:  2012-10-01       Impact factor: 22.113

5.  The effect of ranitidine on cellular immunity in patients with multiple myeloma.

Authors:  H J Nielsen; H Nielsen; F Moesgaard; N Tvede; K Klarlund; B Mansa; A Drivsholm
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 6.  The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.

Authors:  T Dosani; M Carlsten; I Maric; O Landgren
Journal:  Blood Cancer J       Date:  2015-04-17       Impact factor: 11.037

7.  Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.

Authors:  Subhashis Sarkar; Michel van Gelder; Willy Noort; Yunping Xu; Kasper M A Rouschop; Richard Groen; Harry C Schouten; Marcel G J Tilanus; Wilfred T V Germeraad; Anton C M Martens; Gerard M J Bos; Lotte Wieten
Journal:  Cancer Immunol Immunother       Date:  2015-04-29       Impact factor: 6.968

Review 8.  Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.

Authors:  Gianfranco Pittari; Luca Vago; Moreno Festuccia; Chiara Bonini; Deena Mudawi; Luisa Giaccone; Benedetto Bruno
Journal:  Front Immunol       Date:  2017-11-07       Impact factor: 7.561

9.  Biological significance of soluble IL-2 receptor.

Authors:  C Caruso; G Candore; D Cigna; A T Colucci; M A Modica
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

Review 10.  Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.

Authors:  Sabah Akhtar; Tayyiba A Ali; Ammara Faiyaz; Omar S Khan; Syed Shadab Raza; Michal Kulinski; Halima El Omri; Ajaz A Bhat; Shahab Uddin
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.